XORTX Therapeutics Inc. is a late stage biotechnology company focused on discovering developing and potentially commercializing therapies that modulate aberrant purine and uric acid metabolism. The company targets indications such as gout autosomal dominant polycystic kidney disease acute kidney injury linked to respiratory virus infection and type 2 diabetic nephropathy. Its lead program XRx 026 aims to provide a tolerated xanthine oxidase inhibitor formulation for gout patients who cannot use allopurinol. XORTX also advances XRx 008 for autosomal dominant polycystic kidney disease XRx 101 for acute kidney injury and XRx 225 for type 2 diabetic nephropathy. The company’s strategy relies on its proprietary formulation platform XORLO TM which enhances the bioavailability of oxypurinol and incorporates L arginine to support renal protection. XORTX Therapeutics Inc. holds orphan drug designation in the United States for oxypurinol in autosomal dominant polycystic kidney disease which may provide seven years of marketing exclusivity if approved. The firm has secured composition of matter patents in the United States and Europe covering its unique oxypurinol formulations. These intellectual property rights are intended to protect the company’s innovations and support future licensing or partnership opportunities. By concentrating on the purification of uric acid pathways XORTX Therapeutics Inc. seeks to address significant unmet medical needs in renal and metabolic diseases.

As of the date of the filing XORTX Therapeutics Inc. has not generated any product sales revenue because its therapeutic candidates remain in clinical or pre clinical development. The company’s cash inflows derive from financing activities such as private placements registered direct offerings and an at the market offering arrangement with H C Wainwright & Co LLC. In 2024 XORTX Therapeutics Inc. closed two tranches of a non brokered offering that issued 899 717 common share units at a price of CAD 3 per unit for aggregate gross proceeds of approximately US$2 000 549. The company also completed an at the market offering in November 2023 that allowed it to sell common shares up to an aggregate offering price of US$3 701 931 through H C Wainwright & Co LLC. These financing transactions provide the working capital needed to advance its pipeline cover general corporate expenses and support ongoing research and development activities.

XORTX Therapeutics Inc. positions itself as a specialist in xanthine oxidase inhibitor therapy with a focus on formulations that improve drug bioavailability and tolerability. In the gout market the company competes with established uric acid lowering agents such as allopurinol marketed by multiple manufacturers and febuxostat sold by Takeda Pharmaceutical Company Limited. For autosomal dominant polycystic kidney disease the only approved therapy is tolvaptan sold as Jynarque by Otsuka Pharmaceutical Co Ltd which carries a boxed warning for liver toxicity limiting its use. XORTX Therapeutics Inc. differentiates itself through its proprietary XORLO TM formulation which has demonstrated increased bioavailability and a reduced incidence of rash and liver enzyme elevation in clinical studies. The company also holds orphan drug designation in the United States for oxypurinol in autosomal dominant polycystic kidney disease which may provide seven years of marketing exclusivity if approved. XORTX Therapeutics Inc. has received patent protection in the United States and Europe covering its unique oxypurinol formulation methods. The firm’s pipeline includes programs targeting acute kidney injury associated with respiratory virus infection and type 2 diabetic nephropathy expanding its addressable market beyond gout and autosomal dominant polycystic kidney disease. Analyst estimates suggest the global gout market exceeds US$2 billion annually while the autosomal dominant polycystic kidney disease market represents several hundred million dollars in yearly sales. By combining a differentiated product profile with intellectual property protection XORTX Therapeutics Inc. aims to capture a share of these growing markets and establish a competitive position in the renal and metabolic therapeutic space.

XORTX Therapeutics Inc. intends to serve patients suffering from gout autosomal dominant polycystic kidney disease acute kidney injury linked to respiratory virus infection and type 2 diabetic nephropathy. Its therapeutic candidates would be prescribed by nephrologists rheumatologists cardiologists and primary care physicians and would be dispensed through hospitals outpatient clinics and retail pharmacies. While the company has not yet named any commercial partners or distribution agreements it anticipates that health care providers and payers will constitute its primary customer base once its products receive regulatory approval. In addition the company expects that caregivers and patient advocacy groups such as the Polycystic Kidney Disease Foundation will play an important role in educating stakeholders about its therapeutic candidates. These stakeholder relationships are intended to support awareness and uptake of approved treatments should they reach the market.